Development of vaccines for chikungunya fever

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.

Original languageEnglish (US)
Pages (from-to)S488-S496
JournalJournal of Infectious Diseases
StatePublished - Dec 1 2016


  • Alphavirus
  • Arthralgia
  • Chikungunya
  • Vaccine

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Development of vaccines for chikungunya fever'. Together they form a unique fingerprint.

Cite this